Ahmad Osama, Haris Muhammad
Khyber Medical College, Peshawar, Pakistan.
Immun Ageing. 2024 Oct 21;21(1):71. doi: 10.1186/s12979-024-00477-6.
The World Health Organization recognizes frailty and multimorbidity as major global health issues and underscores the need for effective interventions. Recent advances have identified interleukin-11 (IL-11), a pro-inflammatory cytokine, as a key player in modulating aging pathways (such as ERK, AMPK, mTOR and JAK-STAT3). Studies have shown that IL-11 inhibition can lead to improved health span and lifespan in animal models, with potential applications in humans. By targeting IL-11, researchers aim to mitigate age-related diseases, such as cancer, fibrosis, and multimorbidity, which pose significant healthcare challenges worldwide. IL-11 inhibition offers a promising strategy, with preclinical trials demonstrating its ability to regenerate renal cells, reduce hepatocyte death, and mitigate liver fibrosis. Further research is necessary to fully elucidate the mechanisms of IL-11 inhibition and its therapeutic potential. If successful, this approach could lead to the development of novel pharmacological interventions, promoting healthier aging and increasing human lifespan.
世界卫生组织将衰弱和多重疾病视为全球主要的健康问题，并强调需要采取有效的干预措施。最近的研究进展已确定白细胞介素-11（IL-11），一种促炎细胞因子，是调节衰老途径（如ERK、AMPK、mTOR和JAK-STAT3）的关键因素。研究表明，抑制IL-11可延长动物模型的健康寿命和寿命，并在人类中有潜在应用。通过靶向IL-11，研究人员旨在减轻与年龄相关的疾病，如癌症、纤维化和多重疾病，这些疾病在全球范围内构成了重大的医疗挑战。抑制IL-11提供了一种有前景的策略，临床前试验证明其具有再生肾细胞、减少肝细胞死亡和减轻肝纤维化的能力。需要进一步研究以充分阐明抑制IL-11的机制及其治疗潜力。如果成功，这种方法可能会导致新型药物干预措施的开发，促进更健康的衰老并延长人类寿命。
